

ASTar® evaluation data presented at SWACM by leading US Health System Medical Center

Q-linea AB (publ) (OMX:QLINEA) announces a US Health System Medical Center has presented a poster and presentation at the Southwestern Association of Clinical Microbiology (SWACM) 2024 Annual Meeting showing interim results from their evaluation.

Last week, the Southwestern Association of Clinical Microbiology held its annual meeting in St. Louis, Missouri. There, attendees had two opportunities to hear ASTar® evaluation data presented by a leading US research hospital. This event was the first time that ASTar data from a US hospital have been shared publicly.

The poster presentation highlighted key findings, including a greater than 38-hour reduction in time to antibiotic susceptibility test results and an overall 98% total essential agreement and an overall 94% categorical agreement with standard of care methods.

A supporting presentation by a pathologist included additional analytical data and retrospective chart reviews to demonstrate the potential clinical impact of using ASTar. She stated that ASTar results would have supported faster de-escalation of antibiotic therapy in 56% of cases, faster escalation of antibiotic therapy in 18% of cases, and numerous dosage and route of delivery adjustments in other cases.

Jim Kathrein, VP US Commercial Operations, said: “ASTar performance and results are in line with what has been shown previously in several European studies. We look forward to the conclusion of the study, demonstrating how ASTar supports optimization of treatment for patients with bloodstream infections in this setting.”

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

ASTar® evaluation data presented at SWACM by leading US Health System Medical Center